Optimum Strategic Communications’ Post

Are you attending RESI Boston next week? If so, join Portal and Radyus Research for a panel discussion with our Director of Lab and Scientific Operations, Krisha Panchalingam! This panel will discuss maximizing pre-clinical development success for VC-backed startups through CRO partnerships. Additional information is below, and we hope to see you there!

Uncover the Secrets of Biotech IT Evolution: Dive into the 'Calculus of IT' with Nathan McBride of Xilio Therapeutics, Inc. As the biotech industry surges forward, it is imperative to grasp the fundamental elements that define success. From do's and don'ts that can make or break a biotech's journey to finely-tuned launchpad strategies tailored for emerging players in the field, Nate delves into it all in our on-demand video. Watch the whole video here: bit.ly/44oJkq8 For more videos from our Life Sciences Summit, visit: bit.ly/3QwcFeU #LifeSciences #Biotech #ClinicalTrials

Not long after the official divestment of GRAIL, Illumina have now officially acquired single cell multi-omics player Fluent BioSciences Inc.! We feel Illumina are telegraphing their intentions to increase dominance within the growing single cell multi-omics sector, which is poised to hit a market value of$𝟯𝟱 𝗯𝗶𝗹𝗹𝗶𝗼𝗻 𝗯𝘆 𝟮𝟬𝟯𝟯 👀📈 We wish both Illumina & Fluent BioSciences Inc. the utmost success 🫱🏽🫲🏼 #acquistion #multiomics #masonhardingnews

🏥 Akiram Therapeutics: The transition from lab to market We are happy to see Akiram Therapeutics, one of our portfolio companies, featured in Life Science Sweden. The article explores the significant journey undertaken by Marika Nestor, CEO at Akiram, along with her team, who navigated the path from academia at Uppsala University to an established biotech company. This transition, which involved translating research into a viable commercial entity, underscores the challenges and triumphs of moving from lab bench to patient bedside. With Akiram, we see the critical steps of securing funding and navigating patent landscapes to produce novel treatments for clinical trials. Find the full feature (in Swedish) here: https://lnkd.in/dYtCZqtw At Sciety, this is what we do. We invest in life science and health tech companies like Akiram, that have the potential to make a real difference in people's lives. We are a long-term partner supporting the growth of our portfolio companies, whether it be through introductions to potential customers, partners and team members, or operational and strategic advice. Want to learn more about how we work and what we invest in? Visit our website: https://lnkd.in/dQMctGqm #Sciety #VentureCapital #LifeScience

Check out our latest life sciences report, with trends in recent life sciences deal activity.

Known for its abundant forests, smorgasbords, and, of course, the famed Europop group ABBA, Sweden has a thriving economy that largely depends on manufacturing and exports. Plus, the country’s life science sector recorded a net turnover of almost SEK 365 billion ($34 billion) in 2020 – an increase of just over SEK 158 billion ($14.8 billion) since 2014 – and it is still ever-growing. Labiotech.eu discusses eight #biotech companies in Sweden spearheading the country’s biotech scene. * Amferia * Anocca * Aprea Therapeutics * Asgard Therapeutics * BioInvent International AB * Diamyd Medical * Hamlet BioPharma * Modus Therapeutics Holding AB Find out more via https://lnkd.in/ew7FAXYQ

#SwissBiotechDay #AkcesoAdvisors #AndrásIncze Join us at the Swiss Biotech Day next Monday and Tuesday, where our Founder & CEO, Andras Incze, will be serving as a jury member on two pitching sessions! 🎉   The Swiss Biotech Day, hosted by the Swiss Biotech Association, is one of Europe's premier biotechnology conferences, bringing together 2,000 professionals from the global life sciences community.   We are very much looking forward to explore how we at Akceso Advisors could help participating biotechs make sure they maximize the value of their asset. This, by helping them reaching target price for the target patient population, thus maximizing net revenue in an ever-more-challenging pharma landscape.   See you there! ✍ Find the registration link in the first comment.  

🌟 New Insights! 🌟 Don't miss Wilson Sonsini Goodrich & Rosati's latest Quarterly Life Sciences Report. This detailed analysis highlights the trends, key insights and developments in biotech and life sciences. LaunchBio's mission is to empower life sciences startups and foster an environment for innovation, and Wilson Sonsini's report is a great resource for anyone looking to stay informed about the current landscape and future directions in life sciences. Check it out below ⬇ #LifeSciences #Biotech #LaunchBio #WilsonSonsini #WSLifeSciReport

Emerging biotech Intellia Therapeutics, Inc. uses its employer brand to speed up the flywheel, where the reason people apply is the reason they stick around according to TA VP Shaun Vigeant. Here's a snippet from the larger conversation you can find on YouTube. #Biotechnology #TalentAcquisition #EmployerBranding

Learn more about drug discovery assays and how Momentum can help your research!